Evidence map›Paper›PMID 31025571›Full record

ReviewClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants.

Jiuxing Zhang, Juan Xu, Wenlong Zhang, Meiting Jiang, Juan Liu, Lei Xu, Gaofeng Liu, Zhigang Zhao

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiuxing Zhang1 Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Juan Xu1 Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenlong Zhang1 Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Meiting Jiang1 Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Juan Liu1 Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Lei Xu2 Medical Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Gaofeng Liu1 Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0001-5295-0532
Zhigang Zhao3 Department of Pharmacy, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
Harbin Medical University · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated thrombosis (CAT) studies have increased in recent years and the quality of guidelines to guide the clinical practice of CAT prevention and treatment becomes crucial. The therapy status of new oral anticoagulants (NOACs) has been established in some thrombotic diseases, but the evidence for CAT remains unconvincing. The aim of this research is to evaluate the quality of CAT guidelines and discuss the role of NOAC in CAT. A search of articles was performed using PubMed/Medline, Chinese National Knowledge Infrastructure, and other authoritative websites. Search terms included guideline or guidance, consensuses, cancer, and thrombosis. Appraisal of Guidelines for Research & Evaluation II (AGREE II) tool was used to evaluate the qualities of the guidelines. A total of 19 guidelines were screened out and evaluated, of which 8 were recommended, 5 were recommended after revision, and 6 were not recommended. For prevention and treatment of CAT, low-molecular-weight heparin is the most recommended, followed by vitamin K antagonist, unfractionated heparin, fondaparinux, and aspirin. New oral anticoagulant is optional in some cases of CAT treatment. Based on AGREE II assessment tool, the quality of CAT guidelines is inconsistent. Attention should be drawn to the quality of CAT guidelines during clinical practice. The role of NOAC in the treatment of CAT is gradually established but requires more supporting evidence from future clinical trials.

Indexed as

Administration, OralAnticoagulantsFondaparinuxHeparin, Low-Molecular-WeightHumansNeoplasmsPractice Guidelines as TopicThrombosisAnticoagulantsFondaparinuxHeparin, Low-Molecular-WeightAGREE IIcancer-associated thrombosisguidelinenew oral anticoagulantquality appraisal

Identifiers

PMID31025571
PMCPMC6714899
OpenAlexW2941493435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.